Reducing Treatment Burden in Neovascular Age-related Macular Degeneration: What’s Now? What’s Next?
Release Date: September 14, 2018
Last Reviewed: June 28, 2019
Expiration Date: September 14, 2019
Time to Complete Activity:  1.5 hours

*This activity expired for credit on September 14, 2019 and is no longer available for credit

Arshad M. Khanani, MD, MA (Chair)
Clinical Associate Professor
University of Nevada, Reno
Managing Partner and Director of Clinical Research
Sierra Eye Associates
Reno, NV
Sophie J. Bakri, MD
Professor of Ophthalmology
Mayo Clinic
Rochester, MN
Carl D. Regillo, MD, FACS
The Retina Service of Wills Eye Hospital
Professor of Ophthalmology
Thomas Jefferson University
Partner, Mid Atlantic Retina
Philadelphia, PA
This activity is provided by Paradigm Medical Communications, LLC.  
Target Audience
This activity is designed to meet the educational needs of retina specialists and comprehensive ophthalmologists. It may also be of benefit to other clinicians treating patients with neovascular age-related macular degeneration (nAMD).
Statement of Need
Neovascular, or “wet” age-related macular degeneration (nAMD) imposes a high burden on patients and eye care providers alike, as optimal visual outcomes have been contingent on regular (often monthly), ongoing treatment, typically with intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy. This educational webinar will acquaint retina specialists and comprehensive ophthalmologists with new and anxiously awaited treatments and strategies that have the potential to reduce nAMD treatment burden, while maintaining (and possibly enhancing) the long-term visual outcomes and safety associated with conventional dosing protocols and treatments. This activity will also explore both in-office diagnostics and home-based patient tools that can be used to aid early diagnosis, so that treatment can be initiated as soon as possible for optimal visual outcomes.
Learning Objectives
Upon proper completion of this activity, participants should be better able to:
  • Identify early signs of neovascular age-related macular degeneration based on recommended tests.
  • Apply evidence informing the use of dosing strategies for current intravitreal anti-VEGF agents that have been proven to reduce treatment burden without sacrificing long-term visual outcomes in patients with neovascular age-related macular degeneration.
  • Differentiate new and emerging agents and modalities for neovascular age-related macular degeneration, based on clinical profile, mechanism of action, pharmacology, dosing, and delivery, as appropriate.

Table of Contents
• Introduction
• Earlier Detection of nAMD: Better Outcomes, Lower Treatment Burden
• What’s Now? Appropriate Use of Current Anti-VEGF Agents: Dosing Strategies to Reduce nAMD Treatment Burden
• To Inject or Not to Inject?
• What’s Next? Reducing nAMD Treatment Burden: Differentiating Among Current and Emerging Therapies
• Q&A
Physician Accreditation Statement
Paradigm Medical Communications, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physician Credit Designation Statement
Paradigm Medical Communications, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Commercial Support
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
Instructions for Participation
To receive a CME certificate of participation, you should:
  • Follow instructions to register or log in with your professional information and complete the pre-activity assessment
  • View the online activity in its entirety.
  • Complete and submit the online posttest and evaluation.
A certificate of participation will be available for download/printing immediately following your successful completion of the posttest and evaluation.

For questions regarding CME credit, contact the Paradigm CME Department at (845) 398-5949.
There is no fee required for participation in this activity.

Hardware/Software Requirements
This certified CME activity is designed using HTML5 video. As you navigate the video using the supplied controls, the slides will sync to the speaker.
Supported Browsers:
For Desktops (Windows/Mac)
Internet Explorer 9 or higher, Firefox 28 or higher, Safari 5.1 or higher, Google Chrome 31 or higher, Opera 21 or higher
For Tablets (iPad®/Android/Surface)
iOS Safari 4 or higher, Android 2.3 or higher, IE Mobile 10 or higher
Technical Support: If you have any technical problems or playback issues email us at
In accordance with Accreditation Council for Continuing Medical Education requirements on disclosure, faculty and contributors are asked to disclose any relationships with commercial interests associated with the area of medicine featured in the activity. These relationships are described below.
Arshad M. Khanani, MD, MA (Chair)
Grant/Research Support: Allergan, Inc.; Genentech, Inc./Roche; Novartis Pharmaceuticals Corporation; Opthea
Retained Consultant: Allergan, Inc.; Genentech, Inc./Roche; Novartis Pharmaceuticals Corporation
Speakers Bureau: Allergan, Inc.; Genentech, Inc./Roche
Sophie J. Bakri, MD
Retained Consultant: Allergan, Inc.; EyePoint Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Genentech, Inc.; Zeiss
Carl D. Regillo, MD, FACS
Grant/Research Support: Allergan, Inc.; Genentech, Inc.; Iconic Therapeutics, Inc.; Novartis Pharmaceuticals Corporation/Alcon; Regeneron Pharmaceuticals, Inc.
Retained Consultant: Allergan, Inc.; Genentech, Inc.; Iconic Therapeutics, Inc.; Notal Vision, Inc.; Novartis Pharmaceuticals Corporation/Alcon; Shire
Paradigm Medical Communications, LLC, staff members have no financial relationships to disclose.
Peer reviewer, Sunir Garg, MD has the following financial relationships to disclose:
Retained Consultant: Bausch & Lomb; Deciphera Pharmaceuticals, Inc; Santen Pharmaceutical Co., Ltd
Contracted Research: Aerpio; Allergan, Inc; Eyegate
Resolution of Conflict of Interest
Paradigm Medical Communications, LLC, has implemented a system to resolve conflicts of interest for each CME activity to help ensure content is objective, fair and balanced, independent, and aligned with the public interest. Conflicts, if any, are resolved through one or more processes. All CME content in this activity was independently reviewed to ensure that it is free of commercial bias, scientifically rigorous, aligned with the public interest, and compliant with all regulatory guidance and the ACCME’s Standards for Commercial Support of Continuing Medical Education.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.
This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified.
As an ACCME-accredited provider, Paradigm Medical Communications, LLC, activities must include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Paradigm Medical Communications, LLC.
Terms of Use and Privacy Policy
The materials provided for this activity are for informational purposes only, and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. Any views or opinions presented are solely those of the Faculty, and do not necessarily represent those of Paradigm Medical Communications, LLC. References to any entity, product, service, or source of information on this website should not be considered an endorsement, either direct or implied, by Paradigm Medical Communications, LLC. Paradigm Medical Communications, LLC, accepts no liability for the content referenced in this activity.
Privacy policy
Paradigm Medical Communications, LLC, is committed to protecting the privacy of those who participate in the activities (herein referred to as “website") located at The information below describes the security of the website for safeguarding personal information and the rationale for collection and use of personal information.
Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.
Collection and use of your personal information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing the program. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of the CME activity. All evaluative information submitted is collected and retained, and used by Paradigm Medical Communications, LLC, to continuously improve the learning experience.
Paradigm Medical Communications, LLC, does not transfer, sell, or share personal information with outside parties. Paradigm Medical Communications, LLC, will not otherwise disclose personal information unless required to in a legal process. Paradigm Medical Communications, LLC, staff members review individual test results to the extent necessary to record and track participants’ credits.
Contact Us
If you have any questions or comments, please email us at
© 2018 Paradigm Medical Communications, LLC, except where noted. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.